表紙
市場調查報告書

人類胚胎幹細胞的全球市場

Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 567966
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
人類胚胎幹細胞的全球市場 Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

本報告提供人類胚胎幹細胞的全球市場調查,市場概要,各應用領域、地區的市場趨勢,市場促進、阻礙因素及課題分析,競爭情形,主要企業簡介等系統性資訊。

第1章 簡介

  • 市場定義
  • 調查手法

第2章 摘要整理

第3章 主要推論

第4章 市場概要

  • 市場概況
  • 波特的五力分析

第5章 市場動態

  • 推動因素
  • 阻礙因素
  • 市場機會
  • 課題

第6章 市場區隔

  • 人類胚胎幹細胞的全球市場:各應用領域
    • 再生醫療
    • 幹細胞生物學
    • 組織工程
    • 毒性實驗
  • 人類胚胎幹細胞的全球市場:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第7章 競爭情形

  • 合併、收購
  • 新產品的投入
  • 協定、聯盟、合作

第8章 企業簡介

  • Australian Stem Cell Centre
  • BD Biosciences
  • Cellartis AB
  • Millipore Corporation
  • Geron Corporation
  • Invitrogen Corporation
  • Viacyte
  • SA Biosciences Corporation
  • Tataa Biocenter
  • Thermo Scientific
  • Vitrolife AB

第9章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54446

The government funding for the development of regenerative medicine has been increasing in most developed countries, because of its applications in organ transplantation, tissue engineering, and various other applications. In the United States, two major government agencies, National Institutes of Health (NIH) and California Institute of Regenerative Medicine (CIRM), fund almost all the translational researches and regenerative medicine development in the country. It is estimated that the United States government invests around USD 800-900 million every year in stem cell research. Additionally, other factors such as the high prevalence of cardiac and malignant diseases, and rising demand for regenerative medicines are expected to drive the market.

Key Market Trends

Stem Cell Biology Research Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. Stem cell biology research will show better growth, owing to the high prevalence of cardiac and malignant diseases. An article published by the ISSCR (International Society for Stem Cell Research) reported that the stem cells hold potential for the treatment of Parkinson's disease in humans. Recently, one of the market players, International Stem Cell Corporation (ISCO), received the patent covering methods for generating HLA homozygous parthenogenetic human stem cell lines from unfertilized eggs. The patent was issued in Australia. Furthermore, to boost the pace of stem cell research, the government is providing funding opportunities to researchers. Thus, owing to these factors, the market studied is expected to witness a high growth rate over the forecast period.

North America Dominates the Human Embryonic Stem Cells Market

The human embryonic stem cells market is expected to dominate in the North America region owing to extensive research activities, along with high burden of chronic diseases and genetic disorders in the region. The United States also shows a high incidence of other diseases, such as diabetes, heart disease, renal failure, and osteoporosis. Human embryonic stem cells have high potential for use in treatment and may become a standard of care for these diseases. Additionally, the FDA has approved clinical trials, which indicated the use of stem cells. Hence, these factors are expected to influence the growth of the human embryonic stem cells market over the forecast period.

Competitive Landscape

The global players into the human embryonic stem cells market are Becton, Dickinson and Company, Cynata Therapeutics Limited, ESI BIO, Geron Corporation, International Stem Cell Corporation, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc, Thermo Fisher Scientific and ViaCyte, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence of Cardiac and Malignant Diseases
    • 4.2.2 Rising Demand for Regenerative Medicines
    • 4.2.3 Increasing Support from Governments and Government and Private Institutions
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Procedure
    • 4.3.2 Stringent Regulatory Guidelines
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Regenerative Medicine
    • 5.1.2 Stem Cell Biology Research
    • 5.1.3 Tissue Engineering
    • 5.1.4 Toxicology Testing
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Rest of World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Cynata Therapeutics Limited
    • 6.1.3 ESI BIO
    • 6.1.4 Geron Corporation
    • 6.1.5 International Stem Cell Corporation
    • 6.1.6 Merck KGaA
    • 6.1.7 PromoCell GmbH
    • 6.1.8 STEMCELL Technologies Inc
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 ViaCyte, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS